Global Non-Hematological Cancers Market to 2021 - Strong growth driven by increased uptake of low toxicity targeted treatments and versatile biologics

  • ID: 3715492
  • Report
  • Region: Global
  • 183 pages
  • GBI Research
1 of 4
Global Non-Hematological Cancers Market Will Almost Double to $141 Billion by 2021
Global Non-Hematological Cancers Market to 2021 - Strong growth driven by increased uptake of low toxicity targeted treatments and versatile biologics

Summary

In 2012, there were 32.6 million people living with any type of cancer within five years of diagnosis, non-hematological cancers are thought to account for 94% of global cancer prevalence. The key cancer indications of this report, namely breast, colorectal, lung and prostate cancer, constitute approximately 51% of global cancer prevalence.

The risk of cancer increases greatly in patients over the age of 65. As populations are projected to increase, with aging and increasing incidence of obesity, the prevalence of cancer as a genetic disease is only anticipated to increase, thereby acting as a driver for revenue growth.  Typically, chemotherapy has curative or palliative uses depending on whether the patient’s tumors are resectable or unresectable, respectively; however, use of chemotherapies is often reliant on performance status, which is lacking in many cancer patients.

There has been a shift towards developing targeted therapies, which by their nature have less toxicity associated with their use and as a result can be administered to greater numbers of cancer patients, who are commonly elderly and have co-morbidities, therefore increasing the overall survival of this group and the number of treatment cycles they may receive.

Scope

Global revenues for the non-hematological cancer market are forecast to grow at a Compound Annual Growth Rate (CAGR) of 9.86%, from $73 billion in 2014 to $141 billion in 2021
- What is the generic penetration?
- Which drugs will achieve blockbuster status?
Overall, there are 6,484 oncology products in the pipeline, which make it the largest therapy area pipeline
- How does the composition of the pipeline compare with that of the existing market?
- What mechanisms of action are most common for pipeline drugs?
18 of the top 20 pharmaceutical companies will market non-hematological cancer drugs in the forecast period
- How is their revenue share of the non-hematological cancer market set to change?
- What CAGR will these companies register in the forecast period?

Reasons to buy

This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis
- Visualize the composition of the non-hematological cancer market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
- Analyze the non-hematological cancer pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
- Understand the growth in patient epidemiology and market revenues for the non-hematological cancer market globally and across the key players and product types
- Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various non-hematological cancers
- Identify commercial opportunities in the non-hematological cancer deals landscape by analyzing trends in licensing and co-development deals
READ MORE
Note: Product cover images may vary from those shown
2 of 4
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Therapy Area Introduction
2.2 Symptoms
2.3 Etiology and Pathophysiology
2.3.1 Etiology
2.3.2 Pathophysiology
2.3.3 Tumor Initiation
2.3.4 Enhanced Growth, Evasion of Apoptosis and Replicative Immortality
2.3.5 Tumor Metabolic Shift
2.3.6 Tumor Progression, Invasion and Metastasis
2.3.7 Evasion of the Immune Response
2.3.8 Cancer Stem Cells
2.4 Co-morbidities and Complications
2.5 Epidemiology Patterns - Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates
2.5.1 Breast Cancer
2.5.2 Colorectal Cancer
2.5.3 Lung Cancer
2.5.4 Prostate Cancer
2.6 Treatment
2.6.1 Surgery and Radiation Therapy
2.6.2 Chemotherapy
2.6.3 Hormonal Therapies
2.6.4 Targeted Therapies
3 Key Marketed Products
3.1 Overview
3.2 Avastin (bevacizumab)
3.3 Herceptin (trastuzumab)
3.4 Alimta (pemetrexed)
3.5 Zytiga (abiraterone acetate)
3.6 Xtandi (enzalutamide)
3.7 Perjeta (pertuzumab)
3.8 Tarceva (erlotinib hydrochloride)
3.9 Yervoy (ipilimumab)
3.10 Conclusion
4 Pipeline Landscape Assessment
4.1 Overview
4.2 Pipeline Development Landscape
4.3 Molecular Targets in the Pipeline
4.4 Clinical Trials
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.5 Conclusion
4.5 Assessment of Key Pipeline Products
4.5.1 Neratinib - Puma Biotechnology
4.5.2 AZD-4736 - AstraZeneca
4.5.3 LY2835219 - Eli Lilly
4.5.4 LEE-011 - Novartis
4.5.5 JNJ-56021927 - Johnson & Johnson
4.5.6 Tremelimumab - AstraZeneca
4.5.7 Margetuximab - Macrogenics
4.5.8 Conclusion
5 Multi-scenario Market Forecast to 2021
5.1 Overall Market Size
5.2 Generic Penetration
5.3 Revenue Forecast by Molecular Target
5.3.1 Epidermal Growth Factor Receptors
5.3.2 Cyclin-Dependent Kinase 4 and 6
5.3.3 Programmed Cell Death Protein 1 Inhibitor
5.3.4 VEGF Inhibitors
5.3.5 ALK Tyrosine Kinase Receptor
5.3.6 Androgen Receptor Antagonists
5.4 Revenue and Market Share Analysis by Company
5.4.1 Roche - To What Extent Will Newly Approved and Pipeline Product Approvals Offset Avastin’s and Herceptin’s Patent Expiries?
5.4.2 Novartis - Markets Blockbuster Drugs, but How Much of These Revenues Are Related to Non-hematological Cancers?
5.4.3 Bristol-Myers - What Does Limited Product Selection for Non-hematological Cancers Mean for Revenues?
5.4.4 Pfizer - What Do Patent Expiries Mean for Pfizer?
5.4.5 Astellas - Tarceva’s Expiry Effects
5.4.6 Amgen - Growth Despite Multiple Patent Expiries
6 Company Analysis and Positioning
6.1 Company Landscape
6.2 Marketed and Pipeline Portfolio Analysis
7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deals by Region, Year and Value
7.1.2 Deals by Stage of Development and Value
7.1.3 Deals by Molecule Type, Mechanism of Action and Value
7.1.4 Table for Licensing Deals Valued Above $100m
7.2 Co-development Deals
7.2.1 Deals by Region, Year and Value
7.2.2 Deals by Stage of Development and Value
7.2.3 Deals by Molecule Type, Mechanism of Action and Value
7.2.4 Table for Co-development Deals Valued Above $100m
8 Appendix
8.1 References
8.2 Table of All Clinical Stage Pipeline Products
8.3 Abbreviations
8.4 Methodology
8.4.1 Coverage
8.4.2 Secondary Research
8.4.3 Market Size and Revenue Forecasts
8.4.4 Pipeline Analysis
8.4.5 Competitive Landscape
8.5 Contact Us
8.6 Disclaimer

1.1 List of Tables
Table 1: Oncology, Global, Symptoms of Most Prevalent Non-hematological Cancers, 2015
Table 2: Complications Associated with Breast, Colorectal, Lung and Prostate Cancers
Table 3: Oncology, Global, Epidemiology of Most Prevalent Non-hematological Cancers, 2015
Table 4: Optimal and Actual Radiation Therapy Usage Rates, US, 1995-2000
Table 5: Optimal and Actual Chemotherapy Usage Rates, Australia, 2010
Table 6: Oncology Therapeutics Market, Global, Approved Indications for Avastin, 2015
Table 7: Oncology Therapeutics Market, Global, Approved Indications for Herceptin, 2015
Table 8: Oncology Therapeutics Market, Global, Approved Indications for Alimta, 2015
Table 9: Oncology Therapeutics Market, Global, Approved Indications for Zytiga, 2015
Table 10: Oncology Therapeutics Market, Global, Approved Indications for Xtandi, 2015
Table 11: Oncology Therapeutics Market, Global, Approved Indications for Perjeta, 2015
Table 12: Oncology Therapeutics Market, Global, Approved Indications for Tarceva, 2015
Table 13: Oncology Therapeutics Market, Global, Approved Indications for Yervoy, 2015
Table 14: Oncology, Global, Market Size ($bn), 2014-2021
Table 15: Oncology, Global, Usage of Generics Across Key Indications, 2016
Table 16: Oncology Therapeutics Market, Global, Forecast Revenues by Company, 2014-2021
Table 17: Oncology, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006-2016
Table 18: Oncology, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006-2016
Table 19: Oncology, Global, All Clinical Stage Pipeline Products, 2016
Table 20: Abbreviations

1.2 List of Figures
Figure 1: Oncology, Major Markets, Treatment Usage Patterns for Breast Cancer, Patients (‘000), 2014-2021
Figure 2: Oncology, Major Markets, Treatment Usage Patterns for Colorectal Cancer, Patients (‘000), 2014-2021
Figure 3: Oncology, Major Markets, Treatment Usage Patterns for Lung Cancer, Patients (‘000), 2014-2021
Figure 4: Oncology, Major Markets, Treatment Usage Patterns for Prostate Cancer, Patients (‘000), 2014-2021
Figure 5: Non-hematological Cancer, Global, Key Marketed Products and Approved Indications, 2015
Figure 6: Oncology Therapeutics Market, Global, Annual Revenues for Avastin ($bn), 2006-2021
Figure 7: Oncology Therapeutics Market, Global, Annual Revenues for Herceptin ($bn), 2006-2021
Figure 8: Oncology Therapeutics Market, Global, Annual Revenues for Alimta ($bn), 2006-2021
Figure 9: Oncology Therapeutics Market, Global, Annual Revenues for Zytiga ($bn), 2011-2021
Figure 10: Oncology Therapeutics Market, Global, Annual Revenues for Xtandi ($bn), 2012-2021
Figure 11: Oncology Therapeutics Market, Global, Annual Revenues for Perjeta ($bn), 2012-2021
Figure 12: Oncology Therapeutics Market, Global, Annual Revenues for Tarceva ($bn), 2006-2021
Figure 13: Oncology Therapeutics Market, Global, Annual Revenues for Yervoy ($bn), 2011-2021
Figure 14: Oncology Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2016
Figure 15: Oncology Therapeutics Market, Global, Pipeline for Oncology by Stage of Development, Molecule Type and Program Type, 2016
Figure 16: Oncology Therapeutics Market, Global, Pipeline for Key Oncology Indications by Stage of Development, 2016
Figure 17: Oncology Therapeutics Market, Global, Pipeline for Key Oncology Indications by Molecule Type, 2016
Figure 18: Oncology Therapeutics Market, Global, Pipeline for Oncology by Molecular Target, 2016
Figure 19: Oncology Therapeutics Market, Global, Pipeline by Mechanism of Action and Stage of Development, 2016
Figure 20: Oncology Therapeutics Market, Global, Pipeline for Key Oncology Indications by Molecular Target, 2016
Figure 21: Oncology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2016
Figure 22: Oncology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2016
Figure 23: Oncology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2016
Figure 24: Oncology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2016
Figure 25: Oncology Therapeutics Market, Global, Clinical Trial Size by Stage of Development (months), 2006-2016
Figure 26: Oncology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2016
Figure 27: Oncology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2016
Figure 28: Oncology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2016
Figure 29: Oncology Therapeutics Market, Global, Clinical Trial Size by Stage of Development (patients), 2006-2016
Figure 30: Oncology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2016
Figure 31: Oncology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2016
Figure 32: Oncology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2016
Figure 33: Oncology Therapeutics Market, Global, Clinical Program Size by Stage of Development (months), 2006-2016
Figure 34: Oncology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2016
Figure 35: Oncology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2016
Figure 36: Oncology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2016
Figure 37: Oncology Therapeutics Market, Global, Revenue Forecast for neratinib ($m), 2014-2021
Figure 38: Oncology Therapeutics Market, Global, Revenue Forecast for AZD-4736 ($m), 2014-2021
Figure 39: Oncology Therapeutics Market, Global, Revenue Forecast for LY2835219 ($m), 2014-2021
Figure 40: Oncology Therapeutics Market, Global, Revenue Forecast for LEE-011 ($m), 2014-2021
Figure 41: Oncology Therapeutics Market, Global, Revenue Forecast for JNJ-56021927 ($m), 2014-2021
Figure 42: Oncology Therapeutics Market, Global, Revenue Forecast for Tremelimumab ($m), 2014-2021
Figure 43: Oncology Therapeutics Market, Global, Revenue Forecast for Margetuximab ($m), 2014-2021
Figure 44: Oncology, Global, Market Size ($bn), 2014-2021
Figure 45: Oncology, Global, Annual Revenue Forecast for Key Products ($bn), 2014-2021
Figure 46: Oncology, Global, Annual Revenue Forecast for Epidermal Growth Factor Receptors ($bn), 2014-2021
Figure 47: Oncology, Global, Annual Revenue Forecast for Cyclin-Dependent Kinase 4 and 6 ($bn), 2014-2021
Figure 48: Oncology, Global, Annual Revenue Forecast for Programmed Cell Death Protein 1 ($bn), 2014-2021
Figure 49: Oncology, Global, Annual Revenue Forecast for VEGF Inhibitors ($bn), 2014-2021
Figure 50: Oncology, Global, Annual Revenue Forecast for ALK Tyrosine Kinase Receptor ($bn), 2014-2021
Figure 51: Oncology, Global, Annual Revenue Forecast for Androgen Receptor ($bn), 2014-2021
Figure 52: Oncology Therapeutics Market, Global, Forecast Market Share by Company (%), 2014-2021
Figure 53: Oncology, Global, Companies by Compound Annual Growth Rate (%), 2014-2021
Figure 54: Oncology, Global, Revenues by Product Type, 2014-2021
Figure 55: Oncology, Global, Roche Oncology Annual Revenue Forecast ($bn), 2014-2021
Figure 56: Oncology, Global, Novartis AG Annual Revenue Forecast ($m), 2014-2021
Figure 57: Oncology, Global, Bristol-Myers Annual Revenue Forecast ($m), 2014-2021
Figure 58: Oncology, Global, Pfizer Annual Revenue Forecast ($m), 2014-2021
Figure 59: Oncology, Astellas Annual Revenue Forecast ($m), 2014-2021
Figure 60: Oncology, Amgen Annual Revenue Forecast ($m), 2014-2021
Figure 61: Oncology, Global, Companies by Type, 2014-2021
Figure 62: Oncology, Global, Pipeline, High-Activity and Late-Stage Developers by Level of Non-Haematological Cancer Specialization, 2014-2021
Figure 63: Oncology, Global, Proportion of Total Company Revenue Attributed to Non-Haematological Cancer, 2014-2021
Figure 64: Oncology, Global, Licensing Deals, 2006-2016
Figure 65: Oncology, Global, Licensing Deals by Indication and Value, 2006-2016
Figure 66: Oncology, Global, Licensing Deals, 2006-2016
Figure 67: Oncology, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006-2016
Figure 68: Oncology, Global, Co-development Deals, 2006-2016
Figure 69: Oncology, Global, Co-development Deals by Indication and Value, 2006-2016
Figure 70: Oncology, Global, Co-development Deals, 2006-2016
Figure 71: Oncology, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006-2016 116
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll